Cure8 news brief
This trial suggests a new IL‑23 inhibitor, mirikizumab, may be an effective and safe treatment option for adults with moderate-to-severe Crohn's disease who have not responded to prior therapies. Positive phase 3 results could expand treatment choices for people with hard-to-treat disease.
Adults with moderate-to-severe Crohn's disease, patients considering or currently on biologic therapy, gastroenterologists, and IBD researchers.
This article summarizes a large randomized controlled trial reported in The Lancet testing mirikizumab (an IL‑23p19 monoclonal antibody) in adults with moderate-to-severe Crohn's disease who had inadequate response or intolerance to prior therapies.
The trial found that a composite outcome of patient-reported clinical response (week 12) plus endoscopic response (week 52) was significantly greater with mirikizumab than placebo, and clinical remission at week 52 favored mirikizumab. Safety was reported as acceptable in this summary, and the authors note the trial was large and international.
The article also points out a limitation: reliance on non-responder imputation, which can influence estimated treatment effects. If you want original details (exact endpoints, dosing, adverse events, and subgroup results), consult the full Lancet paper linked in the story or discuss with your clinician.
This news piece is a study summary and does not replace medical advice.
The article is a secondary summary of a Lancet randomized controlled trial; it reports primary and key secondary outcomes but does not provide full safety or subgroup data. Non-responder imputation was used, which can affect real-world applicability. No immediate treatment changes are implied without clinician discussion and full trial review.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Long-term maintenance of clinical and endoscopic remission is a key goal in Crohn’s disease care. Positive two-year data and FDA approval may affect treatment options for adults, including people who previously failed...
Longer-term (two-year) results suggest mirikizumab (Omvoh) can maintain clinical and endoscopic benefits for many people with Crohn’s disease, including some with prior biologic failure, which is important when weighing...
This press release reports multi-year data suggesting many patients treated continuously with mirikizumab maintained clinical remission and endoscopic response at two years—outcomes people with Crohn’s disease often care...
